Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress
Globe Newswire•10/11/2026•07:00 ET
0
Key Highlights
- ➤Phase 3 trials planned for severe asthma and CRSwNP in first-quarter 2027
- ➤Cash, equivalents and short-term investments totaled $207.4 million, funding operations through 2027
- ➤Third-quarter net loss widened to $41.2 million from $33.7 million year-over-year
- ➤COPD Phase 2 VENTURE data expected in the second half of 2027
- ➤R&D expenses rose to $36.6 million from $33.0 million year-over-year
Expert Statements
Rand Sutherland, MD, Chief Executive Officer of Upstream Bio
“Our team is focused on the timely execution of startup activities for verekitug’s Phase 3 trials in severe asthma and CRSwNP. Preparations for the planned initiation of these trials in the first quarter of 2027 are well underway, with key clinical, regulatory, and manufacturing milestones now having been achieved.”
Rand Sutherland, MD, Chief Executive Officer of Upstream Bio
“With the substantial and consistent clinical evidence generated across our programs to date, we believe that verekitug has the potential to make a meaningful difference for patients living with these diseases.”
Rand Sutherland, MD, Chief Executive Officer of Upstream Bio
“As we look ahead, we remain focused on advancing verekitug in diseases with significant remaining unmet medical need, where we believe its compelling efficacy profile and convenient quarterly at-home dosing have the opportunity to meaningfully redefine treatment expectations and establish a new standard of care.”
– Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 –
– Prioritizing Phase 3 development strategy designed to deliver best-in-class efficacy and convenient quarterly dosing –
Get started
Create a free account to read the full story.